ARTICLE | Company News

Harbour Biomed in antibody deal with ImmunoChina

January 12, 2018 5:00 PM UTC

Harbour BioMed (Shanghai, China) granted ImmunoChina Pharmaceuticals Co. Ltd. rights to human antibody fragments discovered through its H2L2 transgenic mouse platform for use in developing chimeric antigen receptor (CAR) T cell therapies. Harbour's H2L2 mice generate human mAbs with both heavy and light chains...

BCIQ Company Profiles

HBM Holdings Ltd.